CLN8 disease

CLN8 disease is a rare inherited neurodegenerative disorder belonging to the group of neuronal ceroid lipofuscinoses (NCLs), a family of lysosomal storage diseases. It is caused by mutations in the CLN8 gene, which encodes a transmembrane protein involved in lipid transport and metabolism at the endoplasmic reticulum. CLN8 disease encompasses two clinical phenotypes: a late-infantile variant (also known as Northern epilepsy or progressive epilepsy with intellectual disability, EPMR) and a more severe late-infantile form (Turkish variant late-infantile NCL). The disease primarily affects the central nervous system, leading to progressive neurodegeneration. Key clinical features include seizures (often the presenting symptom), progressive cognitive and motor decline, visual impairment progressing to blindness, speech deterioration, ataxia, and behavioral changes. In the Northern epilepsy variant, onset typically occurs between ages 5 and 10 years with a slower disease progression, while the more severe late-infantile form presents between ages 2 and 7 years with rapid neurological deterioration. Brain imaging often reveals progressive cerebral and cerebellar atrophy. Retinal degeneration contributes to visual loss in many patients. There is currently no cure for CLN8 disease. Treatment is primarily supportive and symptomatic, focusing on seizure management with antiepileptic medications, physical and occupational therapy to maintain function, and palliative care as the disease progresses. Research into gene therapy and other disease-modifying approaches is ongoing, with preclinical studies in animal models showing some promise. Multidisciplinary care involving neurologists, ophthalmologists, geneticists, and rehabilitation specialists is essential for optimizing quality of life.

Common questions about CLN8 disease